Comparative Pharmacology
Head-to-head clinical analysis: OGESTREL 0 5 50 28 versus TRI PREVIFEM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OGESTREL 0 5 50 28 versus TRI PREVIFEM.
OGESTREL 0.5/50-28 vs TRI-PREVIFEM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive; suppresses gonadotropins (FSH, LH) via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation; increases cervical mucus viscosity and alters endometrial development.
Combination oral contraceptive: ethinyl estradiol and norgestimate exert contraceptive effects primarily by suppression of gonadotropin secretion (FSH and LH), thereby inhibiting ovulation. Additionally, progestin induces changes in cervical mucus and endometrial receptivity.
One tablet (norgestrel 0.5 mg/ethinyl estradiol 50 mcg) orally once daily for 28-day cycle.
One tablet (norgestimate 0.180 mg/ethinyl estradiol 0.025 mg) orally once daily for 21 days, followed by 7 days of placebo; repeat cycle.
None Documented
None Documented
Norgestrel: ~45 hours (range 24-56 h) enabling once-daily dosing; Ethinyl estradiol: ~17 hours (range 10-27 h).
Ethinyl estradiol: terminal half-life 13-27 hours; norgestimate: terminal half-life of norelgestromin (active metabolite) 12-30 hours; clinical context: once-daily dosing provides steady-state concentrations within 7-10 days.
Renal: 50-60% as metabolites (glucuronide and sulfate conjugates of norgestrel and ethinyl estradiol); Fecal: 30-40% via biliary elimination; Unchanged drug: <1%.
Ethinyl estradiol: 40% renal, 60% fecal; norgestimate and its metabolites: 80% renal, 20% fecal.
Category C
Category C
Oral Contraceptive
Oral Contraceptive